GlaxoSmithKline Pharma appoints Bhushan Akshikar as new MD; stock jumps ~2%

18 Oct 2022 , 10:26 AM

GlaxoSmithKline Pharma informed that the Board of Directors of the company at its meeting held on October 17, 2022, has appointed Bhushan Akshikar as a Managing Director for a period of four years effective December 1, 2022.

He replaces Sridhar Venkatesh, who will take on a new senior post within the GSK Group on December 1, 2022.

Bhushan Akshikar is a seasoned business executive with over 26 years of experience in local and regional responsibilities in the pharmaceutical sector.

In September 2011, Bhushan joined GSK India to manage specialised and commercial excellence business groups. He was named Head of the Mass Markets business in 2014. In late 2016, he was promoted to Managing Director of GSK’s publicly traded business in Nigeria, Africa.

He not only developed a successful business turnaround, but he also built a high a high-performing, resilient team.

He has developed a strong leadership pipeline, which is reflected in the leadership position and improved competitive performance of numerous GSK marquee products.

Bhushan spent 15 years with Janssen, Johnson & Johnson in different capacities overseeing both specialty and primary care business units in local and regional positions in India, South Korea, and Belgium before joining GSK. Bhushan possesses a postgraduate MBA degree in Marketing from SPJIMR as well as a Bachelor of Pharmaceutical Sciences from the University of Pune.

At around 10.29 AM, Glaxosmithkline Pharmaceuticals was trading at Rs1,396.85 per piece, up by 1.71% from its previous closing of Rs1,373.35 on the BSE. The scrip opened at Rs1,386.30 and touched intraday high and low of Rs1,399 and Rs1,380.45 respectively.

For feedback and suggestions, write to us at [e-mail]